INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder

In schizophrenia,INVEGA SUSTENNA® Has Been Evaluated in >2500 Patients Across 6 Trials1,2:

  • 1 long-term maintenance trial
  • 4 short-term studies in acutely relapsed patients
  • 1 long-term comparative efficacy study

Long-term Maintenance Trial

Adverse reactions occurring in 2% of patients in the long-term maintenance trial3*
A graph illustrating potential INVEGA SUSTENNA® (paliperidone palmitate) adverse reactions and other tolerability information, comparative efficacy study
*Occurring in ≥2% of INVEGA SUSTENNA® patients and more frequently than placebo-treated patients during the double-blind phase.3

Weight Change in Long-term Study

Mean change in body weight from the long-term maintenance study1,4
A graph illustrating potential INVEGA SUSTENNA® (paliperidone palmitate) adverse reactions and other tolerability information, comparative efficacy study
Transition baseline to double-blind endpoint.4

Significant weight gain has been reported with the use of INVEGA SUSTENNA®. Clinical monitoring of weight gain is recommended.1

Weight Gain

From the double-blind baseline to endpoint of the longer-term maintenance study, 6% of patients treated with INVEGA SUSTENNA® had weight gain ≥7% of total body weight vs 3% of placebo-treated patients.1,4

Results from the longer-term, placebo-controlled study of adult patients with schizophrenia. Patients were treated for 33 weeks during an open-label stabilization phase with INVEGA SUSTENNA® (39 mg, 78 mg, or 156 mg every 4 weeks after initiation). Patients were then randomized to this same dose or to placebo in a variable-length, double-blind phase. A preplanned interim analysis was conducted after 68 relapse events.1,4

References: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018. 2. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board–blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 3. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 4. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117.

Content area 1.2